Wall Street stumbles as stimulus talks loom; 3M, McDonald's disappoint
By Devik Jain and Medha Singh (Reuters) - U.S. stocks fell on Tuesday as investors awaited progress on Washington's coronavirus aid plan, with the blue-chip Dow index weighed down by 3M and McDonald's shares after the companies posted quarterly profits that missed estimates. Industrial conglomerate 3M Co dropped 4.3% as it reported a plunge in demand across its business units in the second quarter
By Devik Jain and Medha Singh
(Reuters) - U.S. stocks fell on Tuesday as investors awaited progress on Washington's coronavirus aid plan, with the blue-chip Dow index weighed down by 3M and McDonald's shares after the companies posted quarterly profits that missed estimates.
Industrial conglomerate 3M Co
"This earnings season is a classic example of management sandbagging their second-quarter expectations and the analysts community playing along," said Mike Zigmont, head of trading and research at Harvest Volatility Management in New York.
"It's mostly about beating expectations and if companies don't beat that's the story because it's so rare."
Of the 130 S&P 500 companies that have reported, about 80% of them surpassed significantly lowered forecasts for quarterly profit, according to Refinitiv IBES data, better than the average of 71% companies beating profit estimates over the past four quarters.
A rally in U.S. stocks slowed recently as investors worried about signs of a stalling economic recovery amid a resurgence in coronavirus cases, while awaiting progress on government stimulus talks.
Senate Republicans announced on Monday a $1 trillion aid package hammered out with the White House — four days before millions of Americans lose unemployment benefits — but the proposal sparked immediate opposition from both Democrats and some Republicans.
Latest data showed U.S. consumer confidence ebbed in July amid a flare-up in coronavirus infections across the country.
The U.S. Federal Reserve also said it would extend several of its lending facilities through the end of the year, in a sign the economic impact of the pandemic has been more prolonged than expected.
"The coronavirus has sort of popped back into the consciousness of America and that will dampen enthusiasm a little bit. A small disappointment makes sense because you can't have exuberant confidence forever," Zigmont said.
At 12:44 p.m. ET, the Dow Jones Industrial Average <.DJI> was down 124.30 points, or 0.47%, at 26,460.47 and the S&P 500 <.SPX> was down 4.65 points, or 0.14%, at 3,234.76. The Nasdaq Composite <.IXIC> was down 38.04 points, or 0.36%, at 10,498.22.
A major focus this week will be results from Wall Street's trillion-dollar market value companies - Apple Inc
Industrials <.SPLRCI> and consumer discretionary <.SPLRCD> stocks weighed the most on the benchmark S&P 500 index.
The U.S. central bank is expected to reiterate its accommodative stance when it wraps up its two-day policy meeting on Wednesday afternoon.
Declining issues outnumbered advancers for a 1.07-to-1 ratio on the NYSE and for a 1.45-to-1 ratio on the Nasdaq.
The S&P index recorded 23 new 52-week highs and no new low, while the Nasdaq recorded 47 new highs and 17 new lows.
(Reporting by Devik Jain and Medha Singh in Bengaluru; Editing by Shounak Dasgupta and Maju Samuel)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
(Reuters) - Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion, the Wall Street Journal reported on Saturday, citing people familiar with the matter. A deal for Immunomedics, which last month reported positive data from a late-stage study for its breast-cancer drug, could be announced Monday if not sooner, the Journal said https://www.wsj.com/articles/gilead-nears-deal-to-buy-immunomedics-for-more-than-20-billion-11599936777?mod=hp_lead_pos2. Gilead and Immunomedics did not respond immediately to emailed requests from Reuters for comment
SHANGHAI (Reuters) - China banned pork imports from Germany on Saturday after it confirmed its first case of African swine fever last week, in a move set to hit German producers and push up global prices as China's meat supplies tighten. China's ban on imports from its third largest supplier comes as the world's top meat buyer deals with an unprecedented pork shortage after its own epidemic of the deadly hog disease. The ban on Germany, which has supplied about 14% of China's pork imports so far this year, will push up demand for meat from other major suppliers like the United States and Spain, boosting global prices.
CAIRO (Reuters) - Libyan commander Khalifa Haftar has committed to ending a months-long blockade of oil facilities, the U.S.